^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Glioma

    Related cancers:
    1d
    Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    MB-103
    1d
    Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas (clinicaltrials.gov)
    P1, N=47, Active, not recruiting, Daiichi Sankyo | Phase classification: P=N/A --> P1
    Phase classification
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132
    |
    safusidenib (DS-1001)
    1d
    Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma. (PubMed, Neuro Oncol)
    B7-H3 CAR T cells combined with ONC206 is a feasible and efficacious multi-agent approach against multiple DIPG models.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B) • IFNL1 (Interferon Lambda 1)
    |
    JZP3507
    1d
    Potent antitumor activity through dual targeting of PD-L1 and TGF-β pathways in the glioma tumor microenvironment. (PubMed, J Immunother Cancer)
    Our findings provide strong support for the combined targeting of TGF-β and PD-L1 as a promising immunotherapeutic strategy to overcome immunosuppressive barriers in glioblastoma and induce potent antitumor responses.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    bintrafusp alfa (M7824)
    1d
    A cancer-specific pipeline uncovers MCM3 as a driver of glioblastoma progression via suppression of the Wnt pathway. (PubMed, Int J Biol Macromol)
    Finally, the adaptability of DepMeta was demonstrated through its successful application in identifying analogous targets in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). This research proposes DepMeta as a promising tool for identifying essential pan-cancer genes with stable prognostic value, suggesting a foundation for future development of targeted therapies and personalized treatment strategies.
    Journal • IO biomarker
    |
    MCM3 (Minichromosome maintenance complex component 3)
    1d
    INCIPIENT: CARv3-TEAM-E T Cells in Glioblastoma (clinicaltrials.gov)
    P1, N=21, Recruiting, Marcela V. Maus, M.D.,Ph.D. | Trial primary completion date: Jun 2026 --> Sep 2026 | Trial completion date: Jun 2027 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    EGFR mutation • EGFR amplification
    |
    CARv3-TEAM-E T cells
    2d
    Gliomas with succinate dehydrogenase deficiency: A case series and brief review of the literature of oncometabolite-driven gliomagenesis. (PubMed, J Neuropathol Exp Neurol)
    Here we report 3 cases of diffuse glioma with succinate dehydrogenase deficiency that show many similarities with isocitrate dehydrogenase-mutant gliomas. We propose that succinate dehydrogenase deficiency with accumulation of the oncometabolite succinate can promote gliomagenesis in a similar manner as seen in isocitrate dehydrogenase-mutant and fumarate hydratase-deficient gliomas, and we discuss the proposed mechanisms that may lead to tumor formation.
    Journal
    |
    FH (Fumarate Hydratase)
    2d
    All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma (clinicaltrials.gov)
    P2, N=55, Recruiting, Stephen Bagley, MD, MSCE | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH1 mutation • IDH2 mutation
    |
    Zynyz (retifanlimab-dlwr)
    3d
    NEMO: Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors (clinicaltrials.gov)
    P=N/A, N=600, Not yet recruiting, Tata Memorial Centre | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    3d
    ImproveCodel: A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (clinicaltrials.gov)
    P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2031 --> Mar 2033 | Trial primary completion date: Mar 2031 --> Mar 2033
    Trial completion date • Trial primary completion date • HEOR
    |
    temozolomide • vincristine • lomustine • Matulane (procarbazine hydrochloride)
    3d
    TH-CAR-027 for Grade 4 Gliomas (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Shanghai Tongji Hospital, Tongji University School of Medicine
    New P1 trial
    |
    BRAF (B-raf proto-oncogene) • CD276 (CD276 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • NTRK fusion
    3d
    Mapping of Electrical Properties in the Brain (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Mayo Clinic | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date